Analogues of GLP-1
View Patent ↗The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
1. A method for treating a disease selected from the group consisting of Type I diabetes and Type II diabetes in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound according to the formula (I),
(I)
(R 2 R 3 )-A 7 -A 8 -A 9 -A 10 -A 11 -A 12 -A 13 -A 14 -A 15 -A 16 -A 17 -
A 18 -A 19 -A 20 -A 21 -A 22 -A 23 -A 24 -A 25 -A 26 -A 27 -A 28 -A 29 -A 30 -A 31 -A 32 -
A 33 -A 34 -A 35 -A 36 -A 37 -A 38 -A 39 -R 1 , (SEQ ID NO: 412)
wherein
A 7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;
A 8 is D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;
A 9 is Glu, N-Me-Glu, N-Me-Asp or Asp;
A 10 is Gly, Acc, β-Ala or Aib;
A 11 is Thr or Ser;
A 12 is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X 1 -Phe;
A 13 is Thr or Ser;
A 14 is Ser or Aib;
A 15 is Asp or Glu;
A 16 is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;
A 17 is Ser or Thr;
A 18 is Ser or Thr;
A 19 is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X 1 -Phe;
A 20 is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X 1 -Phe;
A 21 is Glu or Asp;
A 22 is Gly, Acc, β 3 -Ala, Glu or Aib;
A 23 is Gln, Asp, Asn or Glu;
A 24 is Ala, Aib, Val, Abu, Tle or Acc;
A 25 is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O) or NH—CH((CH 2 ) e —X 3 )—C(O);
A 26 is Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O) or NH—CH((CH 2 ) e —X 3 )—C(O);
A 27 is Glu Asp, Leu, Aib or Lys;
A 28 is Phe, Pal, β-Nal, X 1 -Phe, Aic, Acc, Aib, Cha or Trp;
A 29 is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;
A 30 is Ala, Aib or Acc;
A 31 is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;
A 32 is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X 1 -Phe or Ala;
A 33 is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X 1 -Phe;
A 34 is Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O) or NH—CH((CH 2 ) e —X 3 )—C(O);
A 35 is β-Ala, D-Ala, Gaba, Ava, NH—(CH 2 ) m —C(O), Aib, Acc or a D-amino acid;
A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O), NH—CH((CH 2 ) e —X 3 )—C(O) or deleted;
A 37 is Gly, β-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH—(CH 2 ) m —C(O), HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O), a D-amino acid, or deleted;
A 38 is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O), NH—CH((CH 2 ) e —X 3 )—C(O), Ava, Ado, Aec or deleted;
A 39 is D- or L-Lys, D- or L-Arg, HN—CH((CH 2 ) n —N(R 10 -R 11 ))—C(O), Ava, Ado, or Aec;
X 1 for each occurrence is independently selected from the group consisting of (C 1 -C 6 )alkyl, OH and halo;
R 1 is OH, NH 2 , (C 1 -C 30 ) alkoxy, or NH—X 2 —CH 2 —Z 0 , wherein X 2 is a (C 1 -C 12 ) hydrocarbon moiety, and Z 0 is H, OH, CO 2 H or CONH 2 ;
X 3 is
or —C(O)—NHR 12 , wherein X 4 is, independently for each occurrence, —C(O)—, —NH—C(O)— or —CH 2 —, and wherein f is, independently for each occurrence, an integer from 1 to 29 inclusive;
each of R 2 and R 3 is, independently for each occurrence, H;
e is, independently for each occurrence, an integer from 1 to 4 inclusive;
m is, independently for each occurrence, an integer from 5 to 24 inclusive;
n is, independently for each occurrence, an integer from 1 to 5, inclusive;
each of R 10 and R 11 is, independently for each occurrence, H, (C 1 -C 30 )alkyl, (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, —C((NH)(NH 2 )) or
R 12 and R 13 each is, independently for each occurrence, (C 1 -C 30 )alkyl;
provided that:
(i) when A 7 is Ura, Paa or Pta, then R 2 and R 3 are deleted;
(ii) when R 10 is (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl, —C((NH)(NH 2 )) or
then R 11 is H or (C 1 -C 30 )alkyl;
(iii) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -34, -35, -37 or -38)NH 2 or hGLP-1(7-36, -34, -35, -37 or -38)OH;
(iv) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH 2 or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;
(v) a compound of formula (I) is not (Arg 26,34 , Lys 38 )hGLP-1(7-38)-E, (Lys 26 (N ε -alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Lys 34 (N ε -alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Lys 26,34 -bis(N ε -alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Arg 26 , Lys 34 (N ε -alkanoyl))hGLP-1(8-36, -37 or -38)-E, (Arg 26,34 , Lys 36 (N ε -alkanoyl)hGLP-1(7-36, -37 or -38)-E or (Arg 26,34 , Lys 38 (N ε -alkanoyl))hGLP-1(7-38)-E, wherein E is —OH or —NH 2 ;
(vi) a compound of formula (I) is not (Z 1 )-hGLP-1(7-36, -37 or -38)-OH, (Z 1 )-hGLP-1(7-36, -37 or -38)-NH 2 , wherein Z 1 is selected from the group consisting of:
(a) (Arg 26 ), (Arg 34 ), (Arg 26,34 ), (Lys 36 ), (Arg 26 , Lys 36 ), (Arg 34 , Lys 36 ), (D-Lys 36 ),
(Arg 36 ), (D-Arg 36 ), (Arg 26,34 , Lys 36 ) or (Arg 26,36 , Lys 34 );
(b) (Asp 21 );
(c) at least one of (Aib 8 ), (D-Ala 8 ) and (Asp 9 ); and
(d) (Tyr 7 );
(vii) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (vi)(a) to (vi)(d); and
(viii) a compound of formula (I) is not (N-Me-Ala 8 )hGLP-1(8-36 or -37), (G 15 )hGLP-1(7-36 or -37), (Asp 21 )hGLP-1(7-36 or -37), (Phe 31 )hGLP-1(7-36 or -37), or (Aib 8,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:2);
or a pharmaceutically acceptable salt thereof.
2. A method according to claim 1 , wherein A 11 is Thr; A 13 is Thr; A 15 is Asp; A 17 is Ser; A 18 is Ser; A 21 is Glu; A 23 is Gln or Glu; A 27 is Glu; A 31 is Trp.
3. A method according to claim 2 , wherein A 9 is Glu, N-Me-Glu or N-Me-Asp; A 12 is Phe, Acc or Aic; A 16 is Val, Acc or Aib; A 19 is Tyr; A 20 is Leu, Acc or Cha; A 24 is Ala, Aib or Acc; A 25 is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN—CH((CH 2 ) n —N(R 10 R 11 ))—C(O) or HN—CH((CH 2 ) e —X 3 )—C(O); A 28 is Phe; A 29 is Ile or Acc; A 30 is Ala or Aib; A 32 is Leu, Acc or Cha; and A 33 is Val or Acc.
4. A method according to claim 3 , wherein A 8 is D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 10 is Gly; A 12 is Phe, A6c or A5c; A 16 is Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 is Gly, β-Ala or Aib; A 24 is Ala or Aib; A 29 is Ile, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, A6c or A5c; A 35 is Aib, β-Ala, A6c or A5c; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala or deleted.
5. A method according to claim 4 , wherein X 4 for each occurrence is —C(O)—; e for each occurrence is independently 1 or 2; and R 1 is OH or NH 2 .
6. A method according to claim 4 , wherein R 2 is H and R 3 is (C 1 -C 30 )alkyl, (C 2 -C 30 )alkenyl, (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl,
7. A method according to claim 6 , wherein R 10 is (C 1 -C 30 )acyl, (C 1 -C 30 )alkylsulfonyl or
and R 11 is H.
8. A method according to claim 7 , wherein R 10 is (C 4 -C 20 )acyl, (C 4 -C 20 )alkylsulfonyl or
9. A method according to claim 1 , wherein said compound is:
(Aib 8 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:5),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:6),
(Aib 8,35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:7),
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:8),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:9),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -dodecanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:10),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:11),
(Aib 8,35 , Arg 26,34 , Asp 36 (1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:12),
(Aib 8,35 , Arg 26,34 , Asp 36 (1-tetradecylamino))hGLP-1(7-36)NH 2 (SEQ ID NO:13),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl), β-Ala 37 )hGLP-1(7-37)-OH (SEQ ID NO:14) or
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15).
10. A method according to claim 9 , wherein said compound is
(Aib 8 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:5),
(Aib 8,35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:7),
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:8),
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:9), or
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl), β-Ala 37 )hGLP-1(7-37)-OH (SEQ ID NO:14).
11. A method according to claim 1 , wherein said compound is:
(Aib 8 , A6c 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:77);
(Aib 8 , A5c 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:78);
(Aib 8 , D-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:79);
(Aib 8,35 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:16);
(Aib 8,35 , A5c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:80);
(Aib 8,35 , Glu 23 )hGLP-1(7-36)NH 2 (SEQ ID NO:17);
(Aib 8,24,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:18);
(Aib 8,30,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:81);
(Aib 8,25,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:82);
(Aib 8,35 , A6c 16,20 )hGLP-1(7-36)NH 2 (SEQ ID NO:83);
(Aib 8,35 , A6c 16,29,32 )hGLP-1(7-36)NH 2 (SEQ ID NO:84);
(Aib 8,35 , A6c 20,32 )hGLP-1(7-36)NH 2 (SEQ ID NO:85);
(Aib 8,35 , A6c 20 )hGLP-1(7-36)NH 2 (SEQ ID NO:86);
(Aib 8,35 , Lys 25 )hGLP-1(7-36)NH 2 (SEQ ID NO:87);
(Aib 8,24,35 , A6c 20 )hGLP-1(7-36)NH 2 (SEQ ID NO:88);
(Aib 8,35 , A6c 29,32 )hGLP-1(7-36)NH 2 (SEQ ID NO:89);
(Aib 8,24,35 , A6c 29,32 )hGLP-1(7-36)NH 2 (SEQ ID NO:90);
(Aib 8,35 , A6c 12 )hGLP-1(7-36)NH 2 (SEQ ID NO:91);
(Aib 8,35 , Cha 20 )hGLP-1(7-36)NH 2 (SEQ ID NO:92);
(Aib 8,35 , A6c 33 )hGLP-1(7-36)NH 2 (SEQ ID NO:93);
(Aib 8,35 , A6c 20,32 )hGLP-1(7-36)NH 2 (SEQ ID NO:85);
(Aib 8 , A6c 16,20 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:94);
(Aib 8,35 , β-Ala 22 )hGLP-1(7-36)NH 2 (SEQ ID NO:95);
(Aib 8,22,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:96);
(Aib 8,35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:19);
(Aib 8,24,35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:97);
(Aib 8,24,25,35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:98);
(Aib 8,24,25,35 , A6c 16,20,32 , Glu 23 ,)hGLP-1(7-36)NH 2 (SEQ ID NO:99);
(Aib 8 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:100);
(Aib 8 , A5c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:101);
(Aib 8 , Glu 23 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:20);
(Aib 8,24 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:102);
(Aib 8,30 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:103);
(Aib 8,25 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:104);
(Aib 8 , A6c 16,20 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:94);
(Aib 8 , A6c 16,29,32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:105);
(Aib 8 , A6c 20,32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:106);
(Aib 8 , A6c 20 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:107);
(Aib 8 , Lys 25 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:108);
(Aib 8,24 , A6c 20 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:109);
(Aib 8 , A6c 29,32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:110);
(Aib 8,24 , A6c 29,32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:111);
(Aib 8 , A6c 12 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:112);
(Aib 8 , Cha 20 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:113);
(Aib 8 , A6c 33 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:114);
(Aib 8 , A6c 20,32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:106);
(Aib 8 , β-Ala 22,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:115);
(Aib 8,22 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:116);
(Aib 8 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:117);
(Aib 8,24 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:118);
(Aib 8,24 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:119);
(Aib 8,24,25 , Glu 23 , A6c 32 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:120);
(Aib 8,24,25 , A6c 16,20,32 , Glu 23 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:121);
(Aib 8,35 , D-Arg 36 )hGLP-1(7-36)NH 2 (SEQ ID NO:122);
(Aib 8,35 , D-Lys 36 )hGLP-1(7-36)NH 2 (SEQ ID NO:123);
(Aib 8 , β-Ala 35 , D-Arg 36 )hGLP-1(7-36)NH 2 (SEQ ID NO:124);
(Aib 8 , β-Ala 35 , D-Lys 36 )hGLP-1(7-36)NH 2 (SEQ ID NO:125);
(Aib 8,35 , Arg 26,34 ,)hGLP-1(7-36)NH 2 (SEQ ID NO:21);
(Aib 8 , Arg 26,34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:126);
(Aib 8,35 , Arg 25,26,34 )hGLP-1(7-36)NH 2 (SEQ ID NO:127);
(Aib 8 , Arg 25,26 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:128);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);
(Aib 8,35,37 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 )hGLP-1(7-37)OH (SEQ ID NO:132);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);
(Aib 8,35 , Arg 26,34 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);
(Aib 8,35 , Arg 26,34 , Ado 37 )hGLP-1(7-37)OH (SEQ ID NO:138);
(Aib 8,35 , Arg 26,34 , Ado 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:139);
(Aib 8,35 , Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:143);
(Aib 8,35 , Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:144);
(Aib 8,35 , Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:145);
(Aib 8 , Lys 26 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:146);
(Aib 8 , Lys 26 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:147);
(Aib 8 , Lys 26 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:148);
(Aib 8,35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:149);
(Aib 8,35 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:150);
(Aib 8,35 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:151);
(Aib 8,35 , Lys 26 (N ε -decanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:152);
(Aib 8,35 , Lys 25 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:153);
(Aib 8,35 , Lys 25 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:154);
(Aib 8,35 , Lys 25 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:155);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:156);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:157);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:158);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:159);
(Aib 8 , Lys 26 (N ε -octanoyl), Arg 34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:160);
(Aib 8 , Lys 26 (N ε -tetradecanoyl), Arg 34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:161);
(Aib 8 , Lys 26 (N ε -hexadecanoyl), Arg 34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:162);
(Aib 8 , Lys 26 (N ε -decanoyl), Arg 34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:163);
(Aib 8,35 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:164);
(Aib 8,35 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:165);
(Aib 8,35 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:166);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:167);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:168);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:169);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:170);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:171);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:172);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:173);
(Aib 8,35 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:174);
(Aib 8,35 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:175);
(Aib 8,35 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:176);
(Aib 8,35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:177);
(Aib 8,35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:178);
(Aib 8,35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:179);
(Aib 8,35 , Arg 26 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:180);
(Aib 8,35 , Arg 26 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:181);
(Aib 8,35 , Arg 26 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:182);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:183);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:184);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:185);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:186);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:187);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:188);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:189);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:190);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:191);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:192);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:193);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:194);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:195);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -octanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:189);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -decanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:190);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -tetradecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:191);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -hexadecanoyl))hGLP-1(7-38)NH 2 (SEQ ID NO:192);
(Aib 8,35 , Lys 25 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:196);
(Aib 8,35 , Lys 25 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:197);
(Aib 8,35 , Lys 25 , Arg 26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:198);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:199);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:200);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:201);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:202);
(Aib 8 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:203);
(Aib 8 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:204);
(Aib 8 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:205);
(Aib 8 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:206);
(Aib 8 , Glu 23 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:207);
(Aib 8 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:208);
(Aib 8 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:209);
(Aib 8 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:210);
(Aib 8 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:211);
(Aib 8 , Arg 26 , Lys 34 (N ε -decanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:212);
(Aib 8 , Arg 25,26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:213);
(Aib 8 , Arg 25,26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:214);
(Aib 8 , Arg 25,26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:215);
(Aib 8 , Arg 25,26 , Lys 34 (N ε -decanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:216);
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -octanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:217);
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:218);
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:219);
(Aib 8 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:220);
(Aib 8 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:221);
(Aib 8 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:222);
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:223);
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:224);
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:225);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:226);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:227);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:228);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:229);
(Aib 8 , Lys 25 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:230);
(Aib 8 , Lys 25 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl), β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:231);
(Aib 8 , Lys 25 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:232);
(Aib 8 , Arg 25,26 , β-Ala 35 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:233);
(Aib 8 , Arg 25,26,34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:234);
(Aib 8 , Arg 25,26,34 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:235);
(Aib 8 , Arg 25,26,34 , β-Ala 35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:236);
(Aib 8,35 , Lys 26 (N ε -octanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:237);
(Aib 8,35 , Lys 26 (N ε -tetradecanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:238);
(Aib 8,35 , Lys 26 (N ε -hexadecanoyl), A6c 32 , Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:239);
(Aib 8,35 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:240);
(Aib 8,35 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:241);
(Aib 8,35 , A6c 32 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:242);
(Aib 8,35 , Arg 26 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:243);
(Aib 8,35 , Arg 26 , A6c 32 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:244);
(Aib 8,35 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:245);
(Aib 8,35 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:246);
(Aib 8,35 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:247);
(Aib 8,35 , Arg 26 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:248);
(Aib 8,35 , Arg 26 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:249);
(Aib 8,35 , Arg 26 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:250);
(Aib 8,35 , Arg 26,34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:251);
(Aib 8,35 , Arg 26,34 , A6c 32 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:252);
(Aib 8,35 , Arg 26,34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:253);
(Aib 8,35 , Arg 26,34 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:254);
(Aib 8,24,35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:255);
(Aib 8,24,35 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:256);
(Aib 8,24,35 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:257);
(Aib 8,24,35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:258);
(Aib 8,24,35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:259);
(Aib 8,24,35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:260);
(Aib 8,24,35 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:261);
(Aib 8,24,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:262);
(Aib 8,24,35 , Arg 26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:263);
(Aib 8,24,35 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:264);
(Aib 8,35 , Glu 23 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:265);
(Aib 8,35 , Glu 23 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:266);
(Aib 8,35 , Glu 23 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:267);
(Aib 8,35 , Glu 23 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:268);
(Aib 8,35 , Glu 23 , A6c 32 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:269);
(Aib 8,35 , Glu 23 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:270);
(Aib 8,35 , Glu 23 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:271);
(Aib 8,35 , Glu 23 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:272);
(Aib 8,35 , Glu 23 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:273);
(Aib 8,35 , Glu 23 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:274);
(Aib 8,35 , Glu 23 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:275);
(Aib 8,35 , Glu 23 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:276);
(Aib 8,35 , Glu 23 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:277);
(Aib 8,35 , Glu 23 , Arg 26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:278);
(Aib 8,30,35 , Lys 26 (N ε -octanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:279);
(Aib 8,30,35 , Lys 26 (N ε -tetradecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:280);
(Aib 8,30,35 , Lys 26 (N ε -hexadecanoyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:281);
(Aib 8,30,35 , Arg 26 , Lys 34 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:282);
(Aib 8,30,35 , Arg 26 , Lys 34 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:283);
(Aib 8,30,35 , Arg 26 , Lys 34 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:284);
(Aib 8,30,35 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:285);
(Aib 8,30,35 , Arg 26,34 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:286);
(Aib 8,30,35 , Arg 26,34 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:287);
(Aib 8,35 , Glu 23 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:288);
(Aib 8,35 , Glu 23 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:289);
(Aib 8,35 , Glu 23 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:290);
(Aib 8,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:291);
(Aib 8,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:292);
(Aib 8,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:293);
(Aib 8,24,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:294);
(Aib 8,24,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:295);
(Aib 8,24,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:296);
(Aib 8,24,30,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:297);
(Aib 8,24,30,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -tetradecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:298);
(Aib 8,24,30,35 , Glu 23 , Arg 26,34 , A6c 32 , Lys 36 (N ε -hexadecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:299);
(Aib 8,35 , Lys 26 (N ε -octanesulfonyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:317);
(Aib 8,35 , Lys 26 (N ε -dodecanesulfonyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:318);
(Aib 8,35 , Lys 26 (N ε -hexadecanesulfonyl), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:319);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -octanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:320);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -dodecanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:321);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -hexadecanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:322);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -octanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:323);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -hexadecanesulfonyl))hGLP-1(7-36)NH 2 (SEQ ID NO:324);
(Aib 8,35 , Asp 26 (1-(4-decylpiperazine)), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:325);
(Aib 8,35 , Asp 26 (1-(4-dodecylpiperazine)), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:326);
(Aib 8,35 , Asp 26 (1-(4-tetradecylpiperazine)), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:327);
(Aib 8,35 , Asp 26 (1-(4-hexadecylpiperazine)), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:328);
(Aib 8,35 , Arg 26 , Asp 34 (1-(4-decylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:329);
(Aib 8,35 , Arg 26 , Asp 34 (1-(4-dodecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:330);
(Aib 8,35 , Arg 26 , Asp 34 (1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:331);
(Aib 8,35 , Arg 26 , Asp 34 (1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:332);
(Aib 8,35 , Arg 26,34 , Asp 36 (1-(4-decylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:333);
(Aib 8,35 , Arg 26,34 , Asp 36 (1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:335);
(Aib 8,35 , Arg 26,34 , Asp 38 (1-(4-decylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:336);
(Aib 8,35 , Arg 26,34 , Asp 38 (1-(4-dodecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:337);
(Aib 8,35 , Arg 26,34 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:338);
(Aib 8,35 , Arg 26,34 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:339);
(Aib 8,35,37 , Arg 26,34 , Asp 38 (1-(4-decylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:340);
(Aib 8,35,37 , Arg 26,34 , Asp 38 (1-(4-dodecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:341);
(Aib 8,35,37 , Arg 26,34 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:342);
(Aib 8,35,37 , Arg 26,34 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:343);
(Aib 8,35 , Arg 25,34 , Asp 26 (1-(4-decylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:344);
(Aib 8,35 , Arg 25,34 , Asp 26 (1-(4-dodecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:345);
(Aib 8,35 , Arg 25,34 , Asp 26 (1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:346);
(Aib 8,35 , Arg 25,34 , Asp 26 (1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:347);
(Aib 8,35 , Arg 25,26 , Asp 34 (1-(4-decylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:348);
(Aib 8,35 , Arg 25,26 , Asp 34 (1-(4-dodecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:349);
(Aib 8,35 , Arg 25,26 , Asp 34 (1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:350);
(Aib 8,35 , Arg 25,26 , Asp 34 (1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:351);
(Aib 8,35 , Arg 25,26,34 , Asp 36 (1-(4-decylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:352);
(Aib 8,35 , Arg 25,26,34 , Asp 36 (1-(4-dodecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:353);
(Aib 8,35 , Arg 25,26,34 , Asp 36 (1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:354);
(Aib 8,35 , Arg 25,26,34 , Asp 36 (1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH 2 (SEQ ID NO:355);
(Aib 8,35 , Arg 25,26,34 , Asp 38 (1-(4-decylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:356);
(Aib 8,35 , Arg 25,26,34 , Asp 38 (1-(4-dodecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:357);
(Aib 8,35 , Arg 25,26,34 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:358);
(Aib 8,35 , Arg 25,26,34 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:359);
(Aib 8,35,37 , Arg 25,26,34 , Asp 38 (1-(4-decylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:360);
(Aib 8,35,37 , Arg 25,26,34 , Asp 38 (1-(4-dodecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:361);
(Aib 8,35,37 , Arg 25,26,34 , Asp 38 (1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:362);
(Aib 8,35,37 , Arg 25,26,34 , Asp 38 (1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH 2 (SEQ ID NO:363);
(Aib 8,35 , Arg 26,34 , Glu 36 (1-dodecylamino))hGLP-1(7-36)NH 2 (SEQ ID NO:364);
(Aib 8,35 , Glu 26 (1-dodecylamino), Arg 34 )hGLP-1(7-36)NH 2 (SEQ ID NO:365);
(Aib 8,35 , Arg 26 , Glu 34 (1-dodecylamino))hGLP-1(7-36)NH 2 (SEQ ID NO:366);
(Aib 8,35,37 , Arg 26,34 , Glu 38 (1-dodecylamino))hGLP-1(7-38)NH 2 (SEQ ID NO:367);
(Aib 8,35 , Arg 34 , Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:368);
(Aib 8,35 , Arg 34 , Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:369);
(Aib 8,35 , Arg 34 , Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:370;
(Aib 8,35 , Arg 34 , Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:371);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:372);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:373);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:374);
(Aib 8,35 , Arg 26 , Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:375);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:376);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:377);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:378);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:379);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:380);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:381);
(Aib 8,35 , Arg 26,34 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:382);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:383);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:384);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:385);
(Aib 8,35,37 , Arg 26,34 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:386);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:387);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:388);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:389);
(Aib 8,35 , Arg 25,34 , Lys 26 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:390);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:391);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:392);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:393);
(Aib 8,35 , Arg 25,26 , Lys 34 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:394);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:395);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:396);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:397);
(Aib 8,35 , Arg 25,26,34 , Lys 36 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH 2 (SEQ ID NO:398);
(Aib 8,35 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:399);
(Aib 8,35 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:400);
(Aib 8,35 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:401);
(Aib 8,35 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:402);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:403);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:404);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:405);
(Aib 8,35,37 , Arg 25,26,34 , Lys 38 (N ε -(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH 2 (SEQ ID NO:406);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);
(Aib 8,35 , Lys 25 , Arg 26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);
(Aib 8,35 , Arg 26,34 , Ava 37 , Ado 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:409);
(Aib 8,35 , Arg 26,34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1(7-39)NH 2 (SEQ ID NO:27);
(Aib 8,35 , Arg 26,34 , Aun 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:28);
(Aib 8,17,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:29);
(Aib 8 , Arg 26,34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1(7-39)NH 2 (SEQ ID NO:30);
(Aib 8 , Glu 22,23 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:33);
(Aib 8 , Lys 18 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO35);
(Aib 8 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:36);
(Aib 8 , Lys 33 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:37);
(Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:38);
(Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:40);
(Aib 8,27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:41);
(Aib 8,27 , β-Ala 35,37 , Arg 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:42);
(Aib 8,27 , β-Ala 35,37 , Arg 38,39 )hGLP-1(7-39)NH 2 (SEQ ID NO:43);
(Aib 8 , Lys 18,27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:44);
(Aib 8 , Lys 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:45);
(Aib 8 , β-Ala 35 , Arg 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:46);
(Aib 8 , Arg 26,34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:47);
(Aib 8 , D-Arg 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:48);
(Aib 8 , β-Ala 35 , Arg 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:49);
(Aib 8 , Phe 31 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:50);
(Aib 8,35 , Phe 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:51);
(Aib 8,35 , Nal 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:52);
(Aib 8,35 , Nal 28,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:53);
(Aib 8,35 , Arg 26,34 , Nal 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:54);
(Aib 8,35 , Nal 19,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:56);
(Aib 8,35 , Nal 12,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:57);
(Aib 8,35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:58);
(Aib 8,35 , Arg 34 , Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:59);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:60);
(Aib 8 , β-Ala 35 , Ser 37 (O-decanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:61);
(Aib 8,27 , β-Ala 35,37 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 (SEQ ID NO:62);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:63);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:64);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:65);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:410); or
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -dodecanoyl))hGLP-1(8-37)NH 2 (SEQ ID NO:411).
12. A method according to claim 11 , wherein said compound is:
(Aib 8,35 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:16);
(Aib 8,35 , Glu 23 )hGLP-1(7-36)NH 2 (SEQ ID NO:17);
(Aib 8,24,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:18);
(Aib 8,35 , Glu 23 , A6c 32 )hGLP-1(7-36)NH 2 (SEQ ID NO:19);
(Aib 8 , Glu 23 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:20);
(Aib 8,35 , Arg 26,34 )hGLP-1(7-36)NH 2 (SEQ ID NO:21);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -octanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:22);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);
(Aib 8,35 , Lys 25 , Arg 26,34 Lys 36 (N ε -decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 36 (N ε -Aec-decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:25);
(Aib 8,35 , Arg 26,34 , Ava 37 , Ado 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:26);
(Aib 8,35 , Arg 26,34 , Asp 37 , Ava 38 , Ado 39 )hGLP-1(7-39)NH 2 (SEQ ID NO:27);
(Aib 8,35 , Arg 26,34 , Aun 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:28);
(Aib 8,17,35 )hGLP-1(7-36)NH 2 (SEQ ID NO:29);
(Aib 8 , Arg 26,34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 )hGLP-1(7-39)NH 2 (SEQ ID NO:30);
(Aib 8 , Glu 22,23 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:33);
(Aib 8 , Lys 18 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO: 35);
(Aib 8 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:36);
(Aib 8 , Lys 33 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:37);
(Aib 8 , Lys 18 , Leu 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:38);
(Aib 8 , β-Ala 35 , D-Arg 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:40);
(Aib 8,27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:41);
(Aib 8,27 , β-Ala 35,37 , Arg 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:42);
(Aib 8,27 , β-Ala 35,37 , Arg 38,39 )hGLP-1(7-39)NH 2 (SEQ ID NO:43);
(Aib 8 , Lys 18,27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:44);
(Aib 8 , Lys 27 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:45);
(Aib 8 , β-Ala 35 , Arg 38 )hGLP-1(7-38)NH 2 (SEQ ID NO:46);
(Aib 8 , Arg 26,34 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:47);
(Aib 8 , D-Arg 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:48);
(Aib 8 , β-Ala 35 , Arg 37 )hGLP-1(7-37)NH 2 (SEQ ID NO:49);
(Aib 8 , Phe 31 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:50);
(Aib 8,35 , Phe 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:51);
(Aib 8,35 , Nal 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:52);
(Aib 8,35 , Nal 28,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:53);
(Aib 8,35 , Arg 26,34 , Nal 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:54);
(Aib 8,35 , Nal 19,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:56);
(Aib 8,35 , Nal 12,31 )hGLP-1(7-36)NH 2 (SEQ ID NO:57);
(Aib 8,35 , Lys 36 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:58);
(Aib 8,35 , Arg 34 , Lys 26 (N ε -decanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:59);
(Aib 8,35 , Arg 26,34 , Lys 36 (N ε -dodecanoyl))hGLP-1(7-36)NH 2 (SEQ ID NO:60);
(Aib 8 , β-Ala 35 , Ser 37 (O-decanoyl))hGLP-1(7-37)-NH 2 (SEQ ID NO:61);
(Aib 8,27 , β-Ala 35,37 , Arg 38 , Lys 39 (N ε -octanoyl))hGLP-1(7-39)NH 2 (SEQ ID NO:62);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -octanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:63);
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -decanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:64); or
(Aib 8 , Arg 26,34 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl))hGLP-1(7-37)NH 2 (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.
13. A method for treating a disease selected from the group consisting of Type I diabetes and Type II diabetes in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound according to the formula (Aib 8,35 , Arg 26,34 , Phe 31 )hGLP-1(7-36)NH 2 (SEQ ID NO:55),
or a pharmaceutically acceptable salt thereof.
14. A method for treating a disease selected from the group consisting of Type I diabetes and Type II diabetes in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound according to the formula
(Gly 8 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:31),
(Ser 8 , β-Ala 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:32), or
(Gly 8 , Aib 35 )hGLP-1(7-36)NH 2 (SEQ ID NO:34),
or a pharmaceutically acceptable salt thereof.